| Uncovering beta-lactam susceptibility patterns in clinical isolates of Mycobacterium tuberculosis through whole-genome sequencing F Olivença, A Nunes, R Macedo, D Pires, C Silveiro, E Anes, M Miragaia, ... Microbiology Spectrum 10 (4), e00674-22, 2022 | 10 | 2022 |
| The Mycobacteriophage Ms6 LysB N-Terminus Displays Peptidoglycan Binding Affinity AM Gigante, F Olivença, MJ Catalão, P Leandro, J Moniz-Pereira, ... Viruses 13 (7), 1377, 2021 | 8 | 2021 |
| CRISPRi-mediated characterization of novel anti-tuberculosis targets: Mycobacterial peptidoglycan modifications promote beta-lactam resistance and intracellular survival C Silveiro, M Marques, F Olivença, D Pires, D Mortinho, A Nunes, ... Frontiers in Cellular and Infection Microbiology 13, 1089911, 2023 | 7 | 2023 |
| Identification of drivers of mycobacterial resistance to peptidoglycan synthesis inhibitors F Olivença, C Ferreira, A Nunes, C Silveiro, M Pimentel, JP Gomes, ... Frontiers in Microbiology 13, 985871, 2022 | 5 | 2022 |
| Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and intracellular killing of Mycobacterium tuberculosis F Olivença, D Pires, C Silveiro, B Gama, F Holtreman, E Anes, MJ Catalão Antimicrobial Agents and Chemotherapy 68 (4), e01586-23, 2024 | 3 | 2024 |
| Deciphering unexploited features of drug-repurposing beta-lactams against tuberculosis: from genomic patterns of Mycobacterium tuberculosis susceptibility to synergistic … F Olivença | | 2024 |
| WGS-based dual strategy for the identification of key targets to enhance beta-lactam activity in mycobacterium tuberculosis F Olivença, A Nunes, R Macedo, D Pires, C Silveiro, C Ferreira, ... ESCMID/ASM Conference on Drug Development: Meet the Challenge of …, 2022 | | 2022 |
